Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Clinical trial data of BNT162b2 vaccine estimated an early vaccine efficacy in preventing COVID-19 of 52·4% before dose two, and 90.5% on days 2–7 after dose two.2 A recent analysis of BNT162b2 vaccine data estimated vaccine efficacy of 89–91% during days 15–28 after the first dose.3 We examined ear...

Ausführliche Beschreibung